Comparative Pharmacology
Head-to-head clinical analysis: CISATRACURIUM BESYLATE versus CISATRACURIUM BESYLATE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CISATRACURIUM BESYLATE versus CISATRACURIUM BESYLATE PRESERVATIVE FREE.
CISATRACURIUM BESYLATE vs CISATRACURIUM BESYLATE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and causing muscle paralysis.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
Initial IV bolus: 0.15-0.2 mg/kg (2×ED95) for intubation; maintenance: 0.03 mg/kg as needed or continuous infusion at 1-2 mcg/kg/min adjusted to twitch response. Titrate to train-of-four count of 1-2 twitches.
Initial bolus: 0.15-0.2 mg/kg IV; maintenance infusion: 1-3 mcg/kg/min IV titrated to desired neuromuscular blockade.
None Documented
None Documented
Terminal elimination half-life is 22–29 minutes in patients with normal renal and hepatic function; prolonged to ~30–40 minutes in elderly or patients with renal impairment; independent of hepatic function.
Terminal elimination half-life is approximately 22-29 minutes in patients with normal renal and hepatic function. Clinical context: Recovery of neuromuscular function is predictable and independent of organ function due to Hofmann elimination.
Renal (77%) and fecal/biliary (23%); unchanged drug eliminated primarily via renal excretion; Hofmann elimination (non-enzymatic degradation) accounts for ~80% of clearance.
Renal (77%) and fecal (11%) as unchanged drug. Minor hepatic metabolism via Hofmann elimination (non-enzymatic) and ester hydrolysis. No active metabolites.
Category C
Category C
Neuromuscular Blocker (Nondepolarizing)
Neuromuscular Blocker (Nondepolarizing)